Advertisement

Topics

Zymeworks Submits ZW25 Phase 1 Clinical Study Findings Abstract for ASCO 2017

05:00 EST 23 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of...

Other Sources for this Article

Zymeworks
Investor Inquiries:
David Matousek, (604) 678-1388
Senior Manager, Investor Relations & Corporate Communications
ir@zymeworks.com
or
ICR Inc.
Stephanie Carrington, (646) 277-1282
stephanie.carrington@icrinc.com

NEXT ARTICLE

More From BioPortfolio on "Zymeworks Submits ZW25 Phase 1 Clinical Study Findings Abstract for ASCO 2017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...